If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines. The drug, known as CT-388, ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Roche's acquisition of 89bio aims to strengthen its portfolio in cardiovascular, renal, and metabolic diseases, focusing on obesity-related comorbidities like MASH. The merger agreement includes a $14 ...

The deal is set to strengthen Roche’s portfolio in cardiovascular, renal, and metabolic diseases and opens the door to potential combinations with existing programs it is working on, the company said.

FRANKFURT (Reuters) - Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight ...

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KARDIA-3 study, presented today as a late breaker at ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — Roche is following its partner Sarepta Therapeutics and stopping ...

Roche Diagnostics will invest $550 million in its Indianapolis base to construct a new manufacturing facility for glucose monitoring devices, which will add several hundred jobs and further solidify ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning the President Trump administration for an exemption. Roche is trying to ...

Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, making the pharmaceutical giant the latest company to unveil a capital ...

Roche will invest $50 billion in American manufacturing over the next five years, including building a new facility somewhere in Indiana.The Swiss biotech company said the investment will eventually ...